Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101569 | 0.99 | KMT2A (0.43) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7046695 | 0.85 | ALDH1A1 (0.34) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7044554 | 0.85 | ALDH1A1 (0.34) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7047413 | 0.83 | PTGS2 (0.37) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7044725 | 0.75 | L3MBTL1 (0.34) | MAPTSMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL7041986 | 0.72 | KMT2A (0.43) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7101567 | 0.71 | KMT2A (0.41) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7049035 | 0.70 | GRM5 (0.34) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6698332 | 0.70 | KMT2A (0.40) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7043673 | 0.70 | LMNA (0.50) | KMT2AMAPTHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | KMT2A 2560/4885MEN1 4096/4885MAPT 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.